The genes that were most frequently reported in recent subgroup MINAS reports, after BRCA1 and BRCA2, included CHEK2, ATM and FANCM, which would be consistent with these ‘newer’ breast CSGs increasingly being included in gene testing panels for breast/ovarian cancer susceptibility [14–16]. This evidence concerns the gene BRCA2 and ovarian cancer.